ARS Pharmaceuticals
SPRY
77 hedge funds and large institutions have $865M invested in ARS Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 9 closing their positions.
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
25% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 20
13% more funds holding
Funds holding: 68 → 77 (+9)
0.59% more ownership
Funds ownership: 79.6% → 80.19% (+0.59%)
28% less capital invested
Capital invested by funds: $1.21B → $865M (-$341M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$12.2M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$8.79M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.3M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$5.48M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$4.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$10.9M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.37M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.45M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.41M |
| 5 |
VA
VR Adviser
New York
|
-$3.71M |
SPRY Hedge Fund Activity: Q2 2021 in Review
77 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q2 2021, worth a combined $865M — down 28% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SPRY positions and 9 closed out — a net gain of 9 holders — while 25 added to existing stakes and 20 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $12.2M. The largest seller was BlackRock, cutting an estimated $10.9M.
- 77 institutional investors held ARS Pharmaceuticals (SPRY) as of Q2 2021, up from 68 in Q1 2021.
- Funds reported $865M of ARS Pharmaceuticals stock for Q2 2021, down 28% quarter-over-quarter.
- 18 funds opened new ARS Pharmaceuticals positions in Q2 2021 and 9 closed out, a net change of +9 holders.
- The largest ARS Pharmaceuticals buyer in Q2 2021 was Wasatch Advisors, an estimated $12.2M added.
- The largest ARS Pharmaceuticals seller in Q2 2021 was BlackRock, an estimated $10.9M sold.
Based on aggregated 13F filings for Q2 2021.